Experimental Malaria Vaccine Candidate Uses New Target To Stop Parasite’s Growth

News outlets report on a new experimental malaria vaccine candidate.

Deustche Welle: U.S. researchers say a new malaria vaccine candidate stops the parasite mid life cycle
“Most malaria vaccine candidates work by preventing parasites from entering human red blood cells. A newly discovered antibody takes a different approach: it traps the parasites inside the cells…” (Osterath, 5/22).

NPR: Experimental Malaria Vaccine Blocks The Bad Guy’s Exit
“For the first time in decades, researchers trying to develop a vaccine for malaria have discovered a new target they can use to attack this deadly and common parasite…” (Harris, 5/22).

Science: New Malaria Vaccine Shows Promise in Mice
“…[A] study of malaria-resistant children in Tanzania has turned up an antibody that helps stop the infection in its tracks. Based on this antibody’s actions, scientists have developed a preliminary vaccine that shows promise in mice…” (Norton, 5/22).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.